BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment

This work was partly supported by US National Institutes of Health (NIH) grants R01CA113507 and R01CA189224 to M. Xing and by the following additional funding at the individual participating centers: Polish National Center of Research and Development MILESTONE Project-molecular diagnostics and imaging in individualized therapy for breast, thyroid and prostate cancer, grant STRATEGMED2/267398/4/NCBR/2015 (Poland, AC, BJ); grants from Menzies Health Institute, Queensland and Queensland Smart State fellowship (Australia; AKL); grants SAF2013-44709-R (MINECO and FEDER), RD12/0036/0030, PI14/01980 (ISCIII), and GCB14142311CRES (AECC Foundation) (Spain; PS and GRE); grant IG 9338 from the Fondazione Cassa di Risparmio di Perugia and Associazione Italiana per la Ricerca sul Cancro (Italy) and the Beadle Family Foundation (San Antonio, TX; EP); grants AZV 16-32665A and MH CZ-DRO (Institute of Endocrinology-EU, 00023761) (Czech Republic; BB, VS); grants from the New South Wales Cancer Institute (CJO) and Cancer Council of New South Wales (Australia; RCB); NIH/National Institute on Aging grant 5R03AG042334-02 (LY); grants from the Ministero della Istruzione Universitaria e Ricerca Scientifica, the Associazione Italiana per la Ricerca sul Cancro, the Istituto Toscano Tumori, and the Ministero della Salute (Italy; DV, RE); and grants 81471324 from the Natural Science Foundation of China and SHDC12015127 (SQ).